NCT07789678
Epidemiological Profile of Patients With IDH-Mutant Diffuse Gliomas Diagnosed From 2021 in Brazil
Not Yet Recruiting · Not specified · Latin American Cooperative Oncology Group · registry updated 2026-09-04
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This is a real-world, retrospective, non-interventional, single-arm, multi-center Brazilian study that will include patients diagnosed with IDH-mutant diffuse glioma in Brazil from 2021. Eligible patients will be included in this study to have their medical charts data collected by site personnel. Included patients won´t be requested to attend protocol-specific visits and treatment decisions and disease management will be at the investigator's discretion
Inclusion
- Male or female patients (aged 12 years or older);
- Histologically confirmed diagnosis of diffuse glioma from 2021;
- Confirmed IDH mutation identified by IHC or PCR/NGS;
- Willing and able to provide written informed consent, applicable to living patients. In case of patients \<18 years of age, their legal guardians should provide an written informed consent
Exclusion
- Since the study is observational, there are no extensive Exclusion Criteria, but the following criteria excludes patients from the study to ensure data collected by be analyzed from a broader context and compared to other studies of this kind:
- Patients without medical record available (lost, empty or irretrievable clinical information).
- Living patients and/or legal guardians of patients \<18 years of age who did not accept or withdrew their consent from the study.